Spine Biologics Market by Product (Spinal Allografts, Bone Graft Substitutes, and Cell Based Matrix) and Surgery (Open Spine Surgery and Minimally Invasive Spine Surgery) - Global Opportunity Analysis and Industry Forecast, 2014-2022 Update Available On-Demand
|
A01625
|
Pages: 174
|
Mar
2017 |
7922 Views
|
|
|
|
Author(s) :
Deepa Tatkare
|
Tables: 33
|
Charts: 41
|
Formats*:
|
|
COVID-19
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Spine Biologics Market
Request Now !Spine Biologics Market Overview:
Global spine biologics market generated revenue of $1,644 million in 2015, and is projected to reach $2,214 million by 2022, growing at a CAGR of 4.3% during the forecast period. Spine biologics are used during spine fusion surgery for the treatment of spinal deformities such as trauma, tumors, degenerative disc disease, and spinal cord injuries. Increase in geriatric population, advantages of biologics such as minimal postoperative time, faster recovery, and their ability to activate cellular growth are the factors that drive the market growth. However, unfavorable reimbursement scenario, higher cost of the bone grafts, and certain ethical issues related to bone grafting procedures are expected to restrain the growth of the market.
Biologics are used during spinal fusion procedure, as they stimulate bone growth formation through inflammatory stage, repair stage, and remodeling stage. Therefore, rise in number of spinal fusion surgery boosts the use of biologics.
Increase in geriatric population is the major factor anticipated to fuel the demand for biologics in future. For instance, spinal disorders such as spinal stenosis is the most common problem in men and women over 50 years. Aging leads to structural alterations in spine such as thickening of the band of the tissue that supports the spine and enlargement of bones & joints, thus resulting in spinal impairment. According to “Eurostat”, the population of the European Union (EU) was estimated to be 508.5 million on January 1, 2015. Aged population (65 or over) had a share of 18.9%, which showed an increase of 0.4% compared to the previous year. Therefore, older people who are at a higher risk to develop spinal deformities have increased chances to undergo spinal fusion surgery, which in turn is projected to increase the demand for spine biologics.
South Africa: Spine Biologics Market ($Million), 2014-2022
Get more information on this report : Request Sample Pages
On the basis of product type, spine biologics is segmented into spine allografts, bone graft substitutes, and cell-based matrices. The emergence of biologic materials is one of the recent developments of spine fusion surgery. Earlier autografts were considered as the primary bone graft choice; however, owing to various complications related to it such as pain, infection, and weakened bone, allograft evolved as a better treatment option. Presently, bone morphogenetic proteins, bone grafts, and cell-based matrix are used as biologics options. Thus, with continuous development of new products, the use of biologics in spine surgeries is expected to witness a higher demand in the future.
Segmentation
Get more information on this report : Request Sample Pages
The key companies that operate in the spine biologics market are Alphatec Holdings, Inc., Depuy Synthes (Johnson & Johnson), Exactech, Inc., Globus Medical, Inc., Medtronic plc, NuVasive, Inc., Orthofix International N.V., RTI Surgical, Inc., SeaSpine, and Zimmer Biomet Holdings, Inc. Other players include Life Spine, Inc., Nutech, and XTANT MEDICAL.
Key Benefits of the Report
- The study provides an in-depth analysis of the global spine biologics market with current trends and future estimations to elucidate the imminent investment pockets.
- Quantitative analysis from 2014 to 2022 is expected to enable the stakeholders to capitalize on prevailing market opportunities.
- The report provides actual historical figures for 2014 and Y-o-Y forecasts from 2016 to 2022, considering 2015 as base.
- Comprehensive analysis of all geographic regions is provided to determine the prevailing opportunities in these geographies.
- Extensive analysis is conducted by closely following key product positioning and monitoring the top contenders within the market framework.
Spine Biologics Market Key Segments
By Product
- Spinal Allografts
- Machined Bones Allograft
- Demineralized Bone Matrix
- Bone Graft Substitutes
- Bone Morphogenetic Proteins
- Synthetic Bone Grafts
- Cell based Matrix
By Surgery
- Open Spine Surgery
- Minimally Invasive Spine Surgery
By Geography
- North America
- U.S.
- Canada
- Mexico
- Europe
- France
- Germany
- UK
- Spain
- Italy
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
CHAPTER 1 INTRODUCTION
1.1. Key Benefits
1.2. Key Market Segments
1.3. Key Players
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. Key Findings Of The Study
2.2. CXO Perspective
CHAPTER 3 MARKET OVERVIEW
3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top winning strategies
3.2.1.1. Competitive intelligence and strategies of companies
3.2.2. Top investment pockets
3.3. Market Share Analysis, 2015
3.4. Market Dynamics
3.4.1. Drivers
3.4.1.1. Growing elderly population
3.4.1.2. Increasing prevalence of spinal disorders
3.4.1.3. Advantages of biologic materials
3.4.1.4. Shift towards minimal invasive spine procedures
3.4.2. Restraints
3.4.2.1. Higher cost
3.4.2.2. Ethical issues related to grafting
3.4.3. Opportunities
3.4.3.1. Emerging markets to drive the demand for spine biologics
3.4.4. Impact analysis
3.5. Porter's Five Force's Analysis
3.5.1. Bargaining power of buyers
3.5.2. Bargaining power of suppliers
3.5.3. Threat of substitutes
3.5.4. Threat of new entrants
3.5.5. Competitive rivalry
3.6. Government Regulations
CHAPTER 4 GLOBAL SPINE BIOLOGICS MARKET, BY PRODUCT
4.1. OVERVIEW
4.1.1. Key market trends
4.1.2. Growth factors and opportunities
4.1.3. Market size and forecast
4.1.4. Global Spine Biologic Implantations, By Type
4.1.5. Spinal allografts
4.1.5.1. Market size and forecast
4.1.5.1.1. Machined bone allograft
4.1.5.1.1.1. Market size and forecast
4.1.5.1.2. Demineralized bone matrix
4.1.5.1.2.1. Market size and forecast
4.1.6. Bone graft substitutes
4.1.6.1. Market size and forecast
4.1.6.1.1. Bone morphogenetic proteins
4.1.6.1.1.1. Market size and forecast
4.1.6.1.2. Synthetic bone grafts
4.1.6.1.2.1. Market size and forecast
4.1.7. Cell based matrix
4.1.7.1. Market size and forecast
CHAPTER 5 GLOBAL SPINAL IMPLANTS AND DEVICES MARKET, BY SURGERY
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. Open Spine Surgery
5.2.1. Market size and forecast
5.3. Minimally Invasive Spine Surgery
5.3.1. Market size and forecast
CHAPTER 6 GLOBAL SPINE BIOLOGICS MARKET, BY REGION
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. NORTH AMERICA
6.2.1. Key market trends
6.2.2. Growth factors and opportunities
6.2.3. Market size and forecast
6.2.4. U.S. market size and forecast
6.2.5. Canada market size and forecast
6.2.6. Mexico market size and forecast
6.3. EUROPE
6.3.1. Key market trends
6.3.2. Growth factors and opportunities
6.3.3. Market size and forecast
6.3.4. France market size and forecast
6.3.5. Germany market size and forecast
6.3.6. UK market size and forecast
6.3.7. Spain market size and forecast
6.3.8. Italy market size and forecast
6.3.9. Rest of Europe market size and forecast
6.4. ASIA-PACIFIC
6.4.1. Key market trends
6.4.2. Growth factors and opportunities
6.4.3. Market size and forecast
6.4.4. India market size and forecast
6.4.5. China market size and forecast
6.4.6. Japan market size and forecast
6.4.7. South Korea market size and forecast
6.4.8. Australia market size and forecast
6.4.9. Rest of Asia-Pacific market size and forecast
6.5. LAMEA
6.5.1. Key market trends
6.5.2. Growth factors and opportunities
6.5.3. Market size and forecast
6.5.4. Brazil market size and forecast
6.5.5. Saudi Arabia market size and forecast
6.5.6. South Africa market size and forecast
6.5.7. Rest of LAMEA market size and forecast
CHAPTER 7 COMPANY PROFILES
7.1. ALPHATEC HOLDINGS, INC.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating product categories
7.1.4. Business Performance
7.1.5. Key strategic moves and developments
7.2. EXACTECH, INC.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Business performance
7.2.5. Key strategic moves and developments
7.2.6. Key strategic share
7.3. JOHNSON & JOHNSON
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Business performance
7.3.5. Key strategic moves and developments
7.4. GLOBUS MEDICAL, INC.
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating product categories
7.4.4. Business performance
7.4.5. Key strategic moves and developments
7.4.6. Key strategy share
7.5. MEDTRONIC PLC
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Business performance
7.5.5. Key strategic moves and developments
7.5.6. Key strategy share
7.6. NUVASIVE, INC.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Business performance
7.6.5. Key strategic moves and developments
7.6.6. Key strategy share
7.7. ORTHOFIX INTERNATIONAL N.V.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Business performance
7.7.5. Key strategic moves and developments
7.7.6. Key strategy share
7.8. RTI SURGICAL, INC.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Business performance
7.8.5. Key strategic moves and developments
7.8.6. Key strategy share
7.9. SEASPINE
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Business performance
7.9.5. Key strategic moves and developments
7.9.6. Key strategy share
7.10. ZIMMER BIOMET HOLDINGS, INC.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating product categories
7.10.4. Business performance
7.10.5. Key strategic moves and developments
7.10.6. Key strategy share
LIST OF TABLES
TABLE 1. GLOBAL SPINE BIOLOGICS MARKET, BY TYPE ($MILLION), 2014 - 2022
TABLE 2. GLOBAL SPINE BIOLOGICS MARKET, BY REGION ($MILLION), 2014-2022
TABLE 3. GLOBAL SPINE BIOLOGICS IMPLANTATIONS, BY TYPE (THOUSAND UNITS), 2014-2022
TABLE 4. GLOBAL SPINAL ALLOGRAFT MARKET, BY TYPE ($MILLION), 2014 - 2022
TABLE 5. GLOBAL BONE GRAFT SUBSTITUTES MARKET, BY TYPE ($MILLION), 2014 - 2022
TABLE 6. GLOBAL SPINE BIOLOGICS MARKET, BY SURGERY TYPE ($MILLION), 2014-2022
TABLE 7. GLOBAL OPEN SPINE SURGERY MARKET, BY REGION ($MILLION), 2014-2022
TABLE 8. GLOBAL MINIMALLY INVASIVE SPINE SURGERY MARKET, BY REGION ($MILLION), 2014-2022
TABLE 9. GLOBAL SPINE BIOLOGICS MARKET, BY REGION ($MILLION), 2014-2022
TABLE 10. NORTH AMERICA SPINE BIOLOGICS MARKET, BY COUNTRY ($MILLION), 2014-2022
TABLE 11. EUROPE SPINE BIOLOGICS MARKET, BY COUNTRY ($MILLION), 2014-2022
TABLE 12. ASIA-PACIFIC SPINE BIOLOGICS MARKET, BY COUNTRY ($MILLION), 2014-2022
TABLE 13. LAMEA SPINE BIOLOGICS MARKET, BY COUNTRY ($MILLION), 2014-2022
TABLE 14. ALPHATEC: COMPANY SNAPSHOT
TABLE 15. ALPHATEC: PRODUCT CATEGORIES
TABLE 16. EXACTECH: COMPANY SNAPSHOT
TABLE 17. EXACTECH: BUSINESS SEGMENTS
TABLE 18. J&J: COMPANY SNAPSHOT
TABLE 19. J&J: BUSINESS SEGMENTS
TABLE 20. GLOBUS MEDICAL: COMPANY SNAPSHOT
TABLE 21. GLOBUS MEDICAL: PRODUCT CATEGORIES
TABLE 22. MEDTRONIC: COMPANY SNAPSHOT
TABLE 23. MEDTRONIC: BUSINESS SEGMENTS
TABLE 24. NUVASIVE: COMPANY SNAPSHOT
TABLE 25. NUVASIVE: BUSINESS SEGMENTS
TABLE 26. ORTHOFIX: COMPANY SNAPSHOT
TABLE 27. ORTHOFIX: BUSINESS SEGMENTS
TABLE 28. RTI: COMPANY SNAPSHOT
TABLE 29. RTI: BUSINESS SEGMENTS
TABLE 30. SEASPINE: COMPANY SNAPSHOT
TABLE 31. SEASPINE: BUSINESS SEGMENTS
TABLE 32. ZIMMER BIOMET: COMPANY SNAPSHOT
TABLE 33. ZIMMER BIOMET: BUSINESS SEGMENTS
LIST OF FIGURES
FIGURE 1. GLOBAL SPINE BIOLOGICS MARKET, BY TYPE ($MILLION), 2015 VS 2022
FIGURE 2. MARKET SEGMENTATION
FIGURE 3. TOP WINNING STRATEGIES, 2014-2016 (%)
FIGURE 4. TOP WINNING STRATEGIES, ORGANIC AND INORGANIC
FIGURE 5. TOP COMPANIES AND THEIR STRATEGIES
FIGURE 6. DEVELOPMENT STRATEGIES ADOPTED BY COMPANIES
FIGURE 7. TOP INVESTMENT POCKETS
FIGURE 8. MARKET SHARE ANALYSIS, 2015
FIGURE 9. LOW BACK PAIN HEALTH CARE VISITS PER 100 PERSONS, U.S., 2010
FIGURE 10. BARGAINING POWER OF BUYERS, 2015
FIGURE 11. BARGAINING POWER OF SUPPLIERS
FIGURE 12. THREAT OF SUBSTITUTES
FIGURE 13. THREAT OF NEW ENTRANTS
FIGURE 14. COMPETITIVE RIVALRY
FIGURE 15. SPINE BIOLOGICS MARKET FOR MACHINED ALLOGRAFTS ($MILLION), 2014-2022
FIGURE 16. SPINE BIOLOGICS MARKET FOR DEMINERALIZED BONE MATRIX ($MILLION), 2014-2022
FIGURE 17. SPINE BIOLOGICS MARKET FOR BMP ($MILLION), 2014-2022
FIGURE 18. SPINE BIOLOGICS MARKET FOR SYNTHETIC BONE GRAFTS ($MILLION), 2014-2022
FIGURE 19. SPINE BIOLOGICS MARKET FOR CELL BASED MATRIX ($MILLION), 2014-2022
FIGURE 20. FUSION PROCEDURES IN U.S.
FIGURE 21. DISTRIBUTION OF SPINE FUSION PROCEDURE BY SPINE SECTION FOR HOSPITAL DISCHARGE PATIENTS, U.S., 2011
FIGURE 22. U.S.: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 23. CANADA: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 24. MEXICO: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 25. POPULATION STRUCTURE BY MAJOR AGE GROUPS, EU-28
FIGURE 26. FRANCE: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 27. GERMANY: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 28. UK: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 29. SPAIN: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 30. ITALY: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 31. REST OF EUROPE: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 32. INDIA: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 33. CHINA: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 34. JAPAN: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 35. SOUTH KOREA: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 36. AUSTRALIA: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 37. REST OF ASIA-PACIFIC: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 38. BRAZIL: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 39. SAUDI ARABIA: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 40. SOUTH AFRICA: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
FIGURE 41. REST OF LAMEA: SPINE BIOLOGICS MARKET ($MILLION), 2014-2022
Spinal disorders such as spinal stenosis, spondylolisthesis, and scoliosis constitute a major proportion of health and economic burden, hence usage of effective spine biologics during spine surgery becomes a vital need for the treatment of the spinal disorders. To alleviate the aforementioned spine-related disorders and improve patient’s quality of life, spinal surgery is emerging as an ideal treatment option. Thus, rise in demand for spine surgery consequently drives the growth of spine biologics market, as biologics are widely adopted to promote fusion healing, which pedicle screws and rods are unable to provide.
Increase in incidences of spine-related disorders such as stenosis has led to the increase in the adoption of the spinal biologics. In addition, elimination of the need to harvest bone from the patient’s body in a secondary procedure, stimulation of the process of bone growth in spinal fusion surgery, shorter operating times, and reduced hospital stays fuel the growth of the market globally.
Advent of spine surgery treatment is one of the major factors that boosts the market growth. For instance, most of the spine surgeons these days prefer minimal invasive surgical techniques for a wide range of spine fusion procedures, which further use spine biologics. This is attributed to minor complications associated with the procedure such as reduced length of hospital stays and less bleeding.
Geographically, Asia-Pacific offers lucrative growth opportunity for the market due to growth in healthcare expenditure, increase in geriatric population, and rise in incidence of spine impairments. Thus, emerging economies (such as China & India) possess high potential for the market growth in spine biologics.
Download Sample
Purchase Full Report of
Spine Biologics Market- Global Opportunity Analysis and Industry Forecast, 2014-2022
- Online Only
- $2,573
- Online cloud access only
- Restricted print, copy, paste & download
- Read only
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Data Pack
- $2,859
- Restricted to one authorized user
- One print only
- Available in
Excel - Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Single User
- $4,398
- Restricted to one authorized user
- One print only
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Five Users
- $4,803
- Limited to five authorized users
- Print upto five copies
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
-
Enterprise
License/PDF - $6,698
- Unlimited
within
company/enterprise - Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Library Membership
- $ 699/mo
- Published Content
E-access - Company Profiles
E-access - Newly Added Content Access
- 10 PDF
Downloads - 5 Excel Data
Pack Downloads - 250 Company Profiles PDF Downloads
-
Start reading instantly.
Buy Now
This title and over 12,000+ are available on the Avenue Library. Â T&C*.
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers
Get fresh content delivered
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.